Latest On Cue Biopharma, Inc (CUE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 01:40 EST | News | Cue Biopharma GAAP EPS of -$0.29 in-line, revenue of $0.19M misses by $1.76M | N/A |  |
| 2023-03-22 09:56 EST | News | Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-21 18:42 EST | News | Cue Biopharma GAAP EPS of -$0.37 misses by $0.06, revenue of $0.15M beats by $0.05M | N/A | |
| 2023-01-23 14:05 EST | News | Cue biopharma names Matteo Levisetti as new Chief Medical Officer | N/A | |
| 2022-11-15 00:39 EST | News | Cue Biopharma GAAP EPS of -$0.31 beats by $0.07, revenue of $0.07M misses by $0.37M | N/A | |
About Cue Biopharma, Inc (CUE):
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaborat read more...ion agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
General
- Name Cue Biopharma, Inc
- Symbol CUE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 50
- Fiscal Year EndDecember
- IPO Date2018-01-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.cuebiopharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 134.79
- Price/Book (Most Recent Quarter) 5.72
- Enterprise Value Revenue 118.46
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.52
- Next Year EPS Estimate -$1.61
- Next Quarter EPS Estimate -$0.40
- Operating Margin -1428%
- Return on Assets -33%
- Return on Equity -67%
- Revenue 3.15 million
- Earnings Per Share -$2.20
- Revenue Per Share $0.11
- Gross Profit -30391380
- Quarterly Earnings Growth -54.7%
Highlights
- Market Capitalization 408.74 million
- EBITDA -43568648
- PE Ratio -0.75
- Analyst Target Price $30
- Book Value Per Share $2.60
Share Statistics
- Shares Outstanding 30.46 million
- Shares Float 22 million
- % Held by Insiders 1076%
- % Held by Institutions 65.25%
- Shares Short 2.78 million
- Shares Short Prior Month 2.76 million
- Short Ratio 8.92
- Short % of Float 9%
- Short % of Shares Outstanding 9%
Technicals
- Beta 1.91
- 52 Week High $31.69
- 52 Week Low $10.75
- 50 Day Moving Average 14.25
- 200 Day Moving Average 14.04
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Cue Biopharma, Inc (CUE) Dividend Calendar:
Cue Biopharma, Inc (CUE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Cue Biopharma, Inc (CUE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cue Biopharma, Inc (CUE) Chart:
Cue Biopharma, Inc (CUE) News:
Below you will find a list of latest news for Cue Biopharma, Inc (CUE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cue Biopharma, Inc (CUE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CUE Trades:
Cue Biopharma, Inc (CUE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 8-K (Current report) | |
| 2020-08-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-24 | 8-K (Current report) | |
| 2020-08-10 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-15 | 8-K (Current report) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-26 | 8-K (Current report) | |
| 2020-06-25 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | S-3ASR (Automatic shelf registration statement of securities of well-known seasoned issuers) | |
| 2020-06-22 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-06-22 | 8-K (Current report) | |
Cue Biopharma, Inc (CUE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cue Biopharma, Inc (CUE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1076%
Institutional Ownership: 6525%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-03 | Anish Suri | President and CSO | Buy | 33,333.00 | 67,891.00 | | ||
| 2020-09-30 | Cameron Gray | Director | Buy | 5,000.00 | 15.30 | 76,500.00 | 677,500.00 | |
| 2020-09-29 | Cameron Gray | Director | Buy | 5,000.00 | 15.00 | 75,000.00 | 672,500.00 | |
| 2020-08-21 | Kerri-Ann Millar | CFO | Buy | 6,666.00 | 7,666.00 | | ||
| 2020-08-05 | Colin Sandercock | SVP, General Counsel and Sec | Sell | 13,274.00 | 20.00 | 265,480.00 | 17,125.00 | |
| 2020-08-05 | Colin Sandercock | SVP, General Counsel and Sec | Buy | 13,274.00 | 7.50 | 99,555.00 | 30,399.00 | |
| 2020-08-05 | Anish Suri | President and CSO | Sell | 800.00 | 20.01 | 16,008.00 | 34,558.00 | |
| 2020-08-05 | Anish Suri | President and CSO | Buy | 800.00 | 6.42 | 5,136.00 | 35,358.00 | |
| 2020-08-04 | Colin Sandercock | SVP, General Counsel and Sec | Sell | 201.00 | 20.05 | 4,030.05 | 17,125.00 | |
| 2020-08-04 | Colin Sandercock | SVP, General Counsel and Sec | Buy | 201.00 | 7.50 | 1,507.50 | 17,326.00 | |
| 2020-08-04 | Anish Suri | President and CSO | Sell | 400.00 | 20.14 | 8,056.00 | 34,558.00 | |
| 2020-08-04 | Anish Suri | President and CSO | Buy | 400.00 | 6.42 | 2,568.00 | 34,958.00 | |
| 2020-08-03 | Colin Sandercock | SVP, General Counsel and Sec | Sell | 6,425.00 | 20.00 | 128,500.00 | 17,125.00 | |
| 2020-08-03 | Colin Sandercock | SVP, General Counsel and Sec | Buy | 6,425.00 | 7.50 | 48,187.50 | 23,550.00 | |
| 2020-08-03 | Anish Suri | President and CSO | Sell | 5,800.00 | 20.01 | 116,058.00 | 34,558.00 | |
| 2020-08-03 | Anish Suri | President and CSO | Buy | 2,000.00 | 8.26 | 16,520.00 | 36,558.00 | |
| 2020-08-03 | Anish Suri | President and CSO | Buy | 3,800.00 | 6.42 | 24,396.00 | 40,358.00 | |
| 2020-06-24 | Aaron G.L. Fletcher | Director | Buy | 4,547.00 | 24.64 | 112,038.08 | 155,499.00 | |
| 2020-06-24 | Aaron G.L. Fletcher | Director | Buy | 2,953.00 | 25.24 | 74,533.72 | 158,452.00 | |
| 2020-03-31 | Anish Suri | President and CSO | Buy | 16,666.00 | 39,912.00 | |